Ami Patel is a Hematology physician. ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
2000 Circle Of Hope Dr
Suite 2100
Salt Lake City, UT 84112
Telephone
801-585-0120Provider last certified this registry record 11 Nov 2021.
Clinical trials
- Cobimetinib in Newly Diagnosed or HMA-treated CMML Patients With RAS Pathway Mutations
Sponsor: University of Utah
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
5 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Stemline Therapeutics Inc.Program year20251 payment
- Stemline Therapeutics Inc.Program year20241 payment
- SOBI, INCProgram year20241 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
56.5%Antimetabolite23.5%Hydroxyurea100%Part D<11 patientsInterferon alfa-2b13%Besremi100%Part D<11 patients+ 2 more classes in this area
Dermatology
31.3%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor31.3%Acyclovir100%Part D<11 patientsMetabolism & gastrointestinal
12.2%Serotonin-3 Receptor Antagonist12.2%Ondansetron Hcl100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2022–2026 per NIH RePORTER. The latest:
- Mechanisms of resistance to MEK Inhibition in RAS-pathway activated chronic myelomonocytic leukemia
Utah State Higher Education System--University of Utah
FY2026$289,908K08CA252883 - Mechanisms of resistance to MEK Inhibition in RAS-pathway activated chronic myelomonocytic leukemia
Utah State Higher Education System--University of Utah
FY2025$289,908K08CA252883 - Mechanisms of resistance to MEK Inhibition in RAS-pathway activated chronic myelomonocytic leukemia
University of Utah
FY2024$289,908K08CA252883
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Benjamin Ebert, MD
Harvard University
Tait Shanafelt, MD
Palo Alto University
Robert Bast, MD
The University of Texas MD Anderson Cancer Center
Thomas Witzig, MD
Mayo Clinic
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”